临床病例报告杂志

Remission in the Patient with Malignant Pleural Mesothelioma: A Case Report

Abstract

Firsov IS, Sivov IG and Ingenik LLC

Here, we report the patient with Stage IV malignant pleural mesothelioma (MPM), who has reached the remission in 5 months of treatment with experimental targeted product (WO/2017/052419). The remission has been confirmed by PET examination performed in German clinic - as the absence of tumor tissue in primary localization and the absence of the distant metastases. Previous patient’s treatment was not successful. Previous treatments included 6 courses of combined chemotherapy consisted of cisplatin, pemetrexed, and bevacizumab; visceral and parietal pleurectomy combined with hyper-thermic intrathoracic chemotherapy (HITHOC); 6 courses of combined therapy with monoclonal antibodies nivolumab and ipilimumab. All that treatments did not demonstrate necessary clinical effect. The therapy with monoclonal antibodies caused also severe side effects- polyarthritis. Due to all these reasons and significant worsening of patient’s general condition and laboratory parameters, the patient according to his freewill decision started treatment with experimental targeted product (WO/2017/052419) as single anti-tumor agent and in 5 months has reached the remission. General condition improved significantly as well. ECOG score changed from 2-3 points at the therapy start to 0-1 point in 5 months of the treatment. The patient fulfils his routine duties in the office.